Filtered By:
Vaccination: Malaria Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 69 results found since Jan 2013.
Dr. Anthony Fauci Is Stepping Down. Here ’s His Advice For His Successor
After Dr. Anthony Fauci steps down as head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden on Dec. 31, he’ll leave behind a long and storied career. Ahead of his last day, he spoke to TIME from his office at the National Institutes of Health about what’s next for him—and his advice for whoever fills his shoes.
This interview has been edited and condensed for clarity.
TIME: You’re leaving your leadership positions in the federal government, but you aren’t retiring. What are you calling the next stage in your career?
[time-brightc...
Source: TIME: Health - December 20, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Antibody weapon against malaria shows promise in Africa
A new way to prevent malaria that showed promise in 9 U.S. volunteers deliberately exposed to parasite-laden mosquitoes last year has now shown its mettle in a real-world situation in Africa. A study published today in the
New England Journal of Medicine
showed that
a single dose
of lab-produced monoclonal antibodies can protect recipients from infection for up to 6 months during Mali’s intense malaria season.
Monoclonal antibodies are expensive to produce and can be cumbersome to administer if they are infused straight into the bloodstream. That makes some researchers skeptical that the new ones to thwa...
Source: ScienceNOW - November 1, 2022 Category: Science Source Type: news
Anthony Fauci, loved and hated, plots his next move: ‘I'm not going to sit in my house’
In 1984, when Anthony Fauci took over as head of the National Institute of Allergy and Infectious Diseases (NIAID), his wife gave him a plant for the new office. Both the palm and the 81-year-old physician are still there, the giant plant now crowding the office of one of the most celebrated—and polarizing—scientific figures in U.S. history. But not for much longer. Fauci announced on 22 August that he would step down at the end of the year from both NIAID and his post as the chief medical adviser to President Joe Biden.
“What am I going to do with this plant? It’s a monster. I can’t fit it in any other plac...
Source: ScienceNOW - September 1, 2022 Category: Science Source Type: news
Anthony Fauci, loved and hated, plots his next move: ‘I’m not going to sit in my house’
In 1984, when Anthony Fauci took over as head of the National Institute of Allergy and Infectious Diseases (NIAID), his wife gave him a plant for the new office. Both the palm and the 81-year-old physician are still there, the giant plant now crowding the office of one of the most celebrated—and polarizing—scientific figures in U.S. history. But not for much longer. Fauci announced on 22 August that he would step down at the end of the year from both NIAID and his post as the chief medical adviser to President Joe Biden.
“What am I going to do with this plant? It’s a monster. I can’t fit it in any other plac...
Source: ScienceNOW - September 1, 2022 Category: Science Source Type: news
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 develo...
Source: Johnson and Johnson - August 17, 2022 Category: Pharmaceuticals Source Type: news
Investigational malaria vaccine gives strong, lasting protection
(NIH/National Institute of Allergy and Infectious Diseases) Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs -- an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country.
Source: EurekAlert! - Infectious and Emerging Diseases - June 30, 2021 Category: Infectious Diseases Source Type: news
Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice
CONCLUSION The complement-dependent functional immunogenicity of Pfs230D1-EPA represents a significant improvement over Pfs25-EPA in this comparative study. The rhesus model is more predictive of the functional human immune response to Pfs230D1 than is the mouse model.TRIAL REGISTRATION ClinicalTrials.gov NCT02334462.FUNDING Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Source: Journal of Clinical Investigation - April 2, 2021 Category: Biomedical Science Authors: Sara A. Healy, Charles Anderson, Bruce J. Swihart, Agnes Mwakingwe, Erin E. Gabriel, Hope Decederfelt, Charlotte V. Hobbs, Kelly M. Rausch, Daming Zhu, Olga Muratova, Raul Herrera, Puthupparampil V. Scaria, Nicholas J. MacDonald, Lynn E. Lambert, Irfan Za Source Type: research
Top Global Health Moments of 2020
By The Editorial Team,
IntraHealth International
Community Health Nurse Olivia Yeboah thoroughly washes her hands at the Akropong Clinic in Ghana. Photo by Emmanuel Attramah, PMI Impact Malaria/US President ' s Malaria Initiative.December 17, 2020If we wanted to, we could list a COVID-19 moment for every month of 2020. We all know that the onset of the coronavirus pandemic—first in China and then worldwide—overwhelmed news coverage this year. And with good reason. It’s the first large-scale global pandemic in 100 years. At the time this article was pu...
Source: IntraHealth International - December 17, 2020 Category: International Medicine & Public Health Authors: kseaton Tags: HIV & AIDS COVID-19 Nutrition Policy Advocacy Health Workforce Systems Nursing Midwifery 2020 Health Workers Source Type: news
Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection
Malaria is a major disease caused by a parasite transmitted through the bite of infected female mosquitoes. Globally, an estimated 214 million cases of malaria and 438,000 deaths from malaria occur annually, with chidren in African and South Asian regions being most vulnerable. Approximately 1,500-2,000 cases of malaria are reported in the United States each year, mostly in returning travelers from malaria- endemic countries. Among the international travelers, military personnel, diplomats, pregnant women, children and older individuals with weakened immune systems are more likely to be at risk of malaria infection and mor...
Source: NIH OTT Licensing Opportunities - November 13, 2020 Category: Research Authors: ott-admin Source Type: research
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide.
A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news
President Trump Called Hydroxychloroquine a ‘Game Changer,’ But Experts Warn Against Self-Medicating With the Drug. Here’s What You Need to Know
After President Trump, late last week, expressed great confidence in the promise of a new COVID-19 therapy that combines two existing prescription medications, supplies of these two drugs rapidly began disappearing from pharmacy shelves. The U.S. Food and Drug Administration allowed an Indian company previously restricted from importing drug products into the US to now start manufacturing one of the drugs. And U.S. plants began gearing up to produce enough to meet the surge in demand.
But in those few days, a few people who began self medicating with the drugs in an effort to prevent COVID-19 have died, and others have bee...
Source: TIME: Health - March 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
UK still free of coronavirus cases
Patients with symptoms advised to call GP rather than attend practice Related items fromOnMedica Warn patients that natural malaria immunity fades Single-dose malaria drug eliminates parasite from liver Should we have compulsory measles vaccination at school entry? Parents still following folklore methods for cold prevention Double check patients with ‘penicillin’ allergy to avoid MRSA risk
Source: OnMedica Latest News - January 26, 2020 Category: UK Health Source Type: news
GPs should avoid antibiotics for non-bullous impetigo
NICE proposes use of antiseptic creams instead Related items fromOnMedica Single-dose malaria drug eliminates parasite from liver Patients often avoid vaccinations due to fear of side effects Double check patients with ‘penicillin’ allergy to avoid MRSA risk Ibuprofen not a safe alternative to antibiotics for uncomplicated UTIs Inhaled corticosteroids linked to higher infection risk
Source: OnMedica Latest News - August 14, 2019 Category: UK Health Source Type: news
